Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Agilon Health (AGL) Depreciation & Amortization - Total (2020 - 2025)

Agilon Health's Depreciation & Amortization - Total history spans 6 years, with the latest figure at -$10.0 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization - Total fell 38.89% year-over-year to -$10.0 million; the TTM value through Dec 2025 reached $1.5 million, down 6.25%, while the annual FY2025 figure was $1.5 million, 11.76% down from the prior year.
  • Depreciation & Amortization - Total reached -$10.0 million in Q4 2025 per AGL's latest filing, down from $3.8 million in the prior quarter.
  • In the past five years, Depreciation & Amortization - Total ranged from a high of $3.9 million in Q2 2025 to a low of -$10.0 million in Q4 2025.
  • Average Depreciation & Amortization - Total over 5 years is $555000.0, with a median of $1.3 million recorded in 2022.
  • The largest YoY upside for Depreciation & Amortization - Total was 200.0% in 2023 against a maximum downside of 416.67% in 2023.
  • A 5-year view of Depreciation & Amortization - Total shows it stood at $500000.0 in 2021, then soared by 140.0% to $1.2 million in 2022, then tumbled by 416.67% to -$3.8 million in 2023, then tumbled by 89.47% to -$7.2 million in 2024, then tumbled by 38.89% to -$10.0 million in 2025.
  • Per Business Quant, the three most recent readings for AGL's Depreciation & Amortization - Total are -$10.0 million (Q4 2025), $3.8 million (Q3 2025), and $3.9 million (Q2 2025).